Interaction check not available yet — this product's ingredients haven't been matched to our database.
Dietary supplement

MuSolve-SR Ingredients & Drug Interactions

by Tesseract Medical Research

Capsule Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

MuSolve-SR is a dietary supplement by Tesseract Medical Research with 1 active ingredient.Based on those ingredients, 1,069 medications have a known interaction with it, the most serious rated moderate. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of MuSolve-SR by Tesseract Medical Research

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 6 active ingredients.
  • “MuSolve Complex” is a proprietary blend — the label gives one combined amount (300 mg) without saying how much of each component you get.
  • “MuSolve Complex” is a proprietary blend — the label doesn't break down how much of each component you get.

MuSolve-SR contains 6 ingredients, including fenugreek seed, peppermint, eucalyptus, and three botanical components (Syncarpia glomulifera, Pinus, and Bulnesia sarmientoi) grouped as MuSolve Complex. The product also contains inactive ingredients — hypromellose, microcrystalline cellulose, calcium laurate, and plant enzyme — which are fillers and binders in the capsule.

Fenugreek and peppermint are the most extensively studied actives here. Fenugreek is traditionally used to support sexual function, menstrual health, and blood sugar control.

Peppermint is included for digestive comfort, particularly to ease symptoms of irritable bowel syndrome. Eucalyptus adds aromatic and traditional respiratory support properties.

Does it work?

Strong evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed

This product doesn't appear to be marketed for a specific use, so we graded its ingredients' overall clinical evidence instead.

Strong

Strong clinical evidence supports its ingredients for:

Why this rating?
  • We looked at the product name, claims, and label statements and couldn't find a stated purpose to grade.
  • Since the label doesn't commit to one use, we graded the ingredients' overall clinical evidence instead.
  • On file: Irritable bowel syndrome (IBS) — rated "Likely Effective" (Peppermint) (Natural Medicines).
  • On file: Barium enema-related colonic spasm — rated "Possibly Effective" (Peppermint) (Natural Medicines).
  • On file: Chemotherapy-induced nausea and vomiting (CINV) — rated "Possibly Effective" (Peppermint) (Natural Medicines).
  • On file: Dyspepsia — rated "Possibly Effective" (Peppermint) (Natural Medicines).
  • On file: Endoscopy-associated adverse effects — rated "Possibly Effective" (Peppermint) (Natural Medicines).

The evidence for this product's uses comes primarily from its two main checked ingredients. Fenugreek is rated Possibly Effective for sexual dysfunction, sexual arousal, dysmenorrhea (period pain), and diabetes.

Peppermint is rated Likely Effective for irritable bowel syndrome and Possibly Effective for indigestion, nausea from chemotherapy, and muscle spasm during medical procedures. Eucalyptus has not been rated with reliable evidence for the conditions in our data — acne, bronchitis, asthma, burns, and cancer are all listed as Insufficient Reliable Evidence To Rate.

We hold no effectiveness data for the three other botanical ingredients in MuSolve Complex.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Fenugreek seed is generally well tolerated in food amounts, but supplement doses may cause abdominal pain, bloating, diarrhea, indigestion, gas, nausea, and — rarely — severe allergic reactions including throat swelling, breathing problems, and shock. Fenugreek use in late pregnancy may cause an unusual body odor in the newborn that can be confused with maple syrup urine disease, though this appears temporary.

Peppermint and eucalyptus are generally well tolerated; common peppermint side effects are mild (abdominal pain, heartburn, nausea), and eucalyptus diluted for use is safe, though the undiluted oil is toxic if swallowed — large doses can cause serious nervous system effects, shallow breathing, and seizures. All three checked ingredients have rare allergic reactions on record.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Eucalyptus, Peppermint, Fenugreek.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 1,070 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking MuSolve-SR, check with us if you take any blood thinners (anticoagulants or antiplatelet drugs like warfarin, clopidogrel, or aspirin), diabetes medications, seizure drugs (especially phenytoin), theophylline for asthma, metoprolol for blood pressure, sildenafil for erectile dysfunction, cyclosporine for immune suppression, or any drug that's cleared by your liver's CYP3A4, CYP2C9, CYP2C19, or CYP1A2 enzymes — these represent the main Moderate-severity risks. No interactions are documented for the three ingredients we could not check.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with strong clinical evidence behind its ingredients' uses. Moderate medication interactions have been identified, and safety information is well characterized.

MuSolve-SR may be worth considering if you're interested in traditional support for sexual function, digestion, or menstrual comfort, and if you have no major drug interactions. However, because fenugreek affects blood thinners, diabetes drugs, and several other medication categories — and peppermint and eucalyptus alter how your liver clears many drugs — you absolutely must check your medications against the tool on this page before you start.

Talk to your pharmacist or doctor if you take any prescription medications or if you're pregnant or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 6 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated May 21, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about MuSolve-SR, straight from the product label.

Brand Tesseract Medical Research
Net contents 90 Vegetarian Capsule(s)
Market status On market
Date entered into DSLD May 21, 2025
DSLD ID 328493
Product type Other Combinations
Supplement form Capsule
Dietary claims / uses All Other
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for MuSolve-SR by Tesseract Medical Research, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
90
IngredientAmount% DV
Fenugreek0 NP--
MuSolve Complex300 mg--
Peppermint0 NP--
MuSolve Complex0 NP--
Eucalyptus0 NP--
Syncarpia glomulifera0 NP--
Pinus0 NP--
Bulnesia sarmientoi0 NP--

Other ingredients: Hypromellose, Hydroxypropyl Methylcellulose, Microcrystalline Cellulose, Calcium Laurate, Plant Enzyme

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

Suggested use: Take 1 capsule two times daily or as recommended by your health-care practitioner.

Precautions

Tamper evident: Use only if bottle is sealed.

If pregnant, consult your health-care practitioner before using this product.

Storage

Store tightly sealed in a cool, dry place.

Formulation

Sustained release Hypoallergenic

FDA Statement of Identity

Dietary Supplement

Formula

Solubility enhanced ingredients in CyLoc, dextrin fiber matrix molecular traps. CyLoc complexes compounded with Dexkey release agents (patent pending, Al Czap, Czap R&D, licensed by Tesseract Medical Research, LLC).

Brand IP Statement(s)

Solubility enhanced ingredients in CyLoc, dextrin fiber matrix molecular traps. CyLoc complexes compounded with Dexkey release agents (patent pending, Al Czap, Czap R&D, licensed by Tesseract Medical Research, LLC).

See for yourself

MuSolve-SR by Tesseract Medical Research label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in MuSolve-SR by Tesseract Medical Research

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container90 Amounts shown are per serving.

MuSolve Complex

300 mg per serving
  • › MuSolve Complex

Other (inactive) ingredients: Hypromellose, Hydroxypropyl Methylcellulose, Microcrystalline Cellulose, Calcium Laurate, Plant Enzyme. These complete the product’s ingredient list but are not active constituents.

Interaction report

MuSolve-SR by Tesseract Medical Research Drug Interactions

Want to check YOUR meds against MuSolve-SR?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,069Drugs
947 Moderate 122 Minor

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in MuSolve-SR with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

The maker

Brand information

Manufacturer and brand details for MuSolve-SR, from the product label.

Tesseract Medical Research

See all Tesseract Medical Research products
Name
Tesseract Medical Research, LLC
Street Address
1370 Trancas St., #376
City
Napa
State
CA
ZipCode
94558
Web Address
www.TessMed.com
Pharmacist Counseling Corner

MuSolve-SR by Tesseract Medical Research: Common Questions

Does MuSolve-SR by Tesseract Medical Research interact with any medications?
Yes. Based on its ingredients, MuSolve-SR has a known interaction with 1,069 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
MuSolve-SR contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is MuSolve-SR safe to use if I'm pregnant or breastfeeding?
Not during pregnancy — fenugreek is rated Likely Unsafe in pregnancy because it may affect the uterus and cause an unusual body odor in the newborn. For breastfeeding, fenugreek is Possibly Safe and is sometimes used to boost milk supply, but you should discuss it with your doctor or midwife first. Peppermint and eucalyptus are rated Likely Safe in pregnancy and lactation, but concentrated supplements of either should be checked with your provider. We don't have pregnancy or breastfeeding safety data on file for the other three botanical ingredients.
What is fenugreek used for in this product?
Fenugreek seed is included for its traditional use in supporting sexual function and arousal, as well as for menstrual comfort and blood sugar management. The evidence rates it Possibly Effective for sexual dysfunction and arousal, dysmenorrhea (period pain), and diabetes.
Can MuSolve-SR help with my digestion?
Peppermint in this product is rated Likely Effective for irritable bowel syndrome and Possibly Effective for indigestion, so yes — if IBS or mild digestive upset is what you're after, peppermint has good evidence. The eucalyptus and other botanicals in the blend don't have rated effectiveness data for digestive conditions in our records.
What are the most common side effects I might notice?
From fenugreek, the most common are abdominal pain, bloating, diarrhea, gas, and nausea. Peppermint can cause abdominal pain, heartburn, and nausea. Eucalyptus when diluted is generally mild, but concentrated oil taken by mouth can cause diarrhea, nausea, and vomiting. Stop and contact your doctor if you notice severe allergic reactions like throat swelling or trouble breathing — these are rare but serious.
Why can't you check three of the ingredients in this product?
Syncarpia glomulifera, Pinus, and Bulnesia sarmientoi are botanical ingredients that we don't currently hold monographs for, so we have no interaction or effectiveness data on file for them. That doesn't mean they're unsafe or ineffective — we simply haven't assessed them in our database.
Is there any ingredient in MuSolve-SR with no documented drug interactions?
Among the three ingredients we could check thoroughly, all have documented interactions with various medications. The three we couldn't check — Syncarpia glomulifera, Pinus, and Bulnesia sarmientoi — have no data in our system, so we can't say either way. Use the medication checker on this page to see if your specific drugs are affected.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if MuSolve-SR is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

MuSolve-SR label
Sources

Sources & How We Checked

MuSolve-SR's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 94 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Fenugreek 30 references
  1. Madar Z, Thorne R. Dietary fiber. Prog Food Nutr Sci 1987;11:153-74.
  2. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr 1990;44:301-6.
  3. Patil SP, Niphadkar PV, Bapat MM. Allergy to fenugreek (Trigonella foenum graecum). Ann Allergy Asthma Immunol 1997;78:297-300. PubMed
  4. Lambert J, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001;21:509-12. PubMed
  5. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty PubMed
  6. Yalcin SS, Tekinalp G, Ozalp I. Peculiar odor of traditional food and maple syrup urine disease. Pediatr Int 1999;41:108-9. PubMed
  7. Sewell AC, Mosandl A, Bohles H. False diagnosis of maple syrup urine disease owing to ingestion of herbal tea. N Engl J Med 1999;341:769.. PubMed
  8. Abdo MS, al-Kafawi AA. Experimental studies on the effect of Trigonella foenum-graecum (abstract). Planta Med 1969;17:14-8.
  9. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India 2001;49:1057-61.
  10. Gabay MP. Galactogogues: medications that induce lactation. J Hum Lact 2002;18:274-9. PubMed
  11. Chevassus H, Gaillard JB, Farret A, et al. A fenugreek seed extract selectively reduces spontaneous fat intake in overweight subjects. Eur J Clin Pharmacol 2010;66(5):449-55. PubMed
  12. Turkyilmaz C, Onal E, Hirfanoglu IM, et al. The effect of galactagogue herbal tea on breast milk production and short-term catch-up of birth weight in the first week of life. J Altern Complement Med 2011;17(2):139-42. PubMed
  13. Swafford S, Berens P. Effect of fenugreek on breast milk volume. Abstract presented at: 5th International Meeting of the Academy of Breastfeeding Medicine; September 11-13,2000, Tucson, Arizona.
  14. Abdel-Barry, J. A., Abdel-Hassan, I. A., Jawad, A. M., and al Hakiem, M. H. Hypoglycaemic effect of aqueous extract of the leaves of Trigonella foenum-graecum in healthy volunteers. East Mediterr.Health J 2000;6(1):83-88. DOI
  15. Parvizpur, A., Ahmadiani, A., and Kamalinejad, M. Probable role of spinal purinoceptors in the analgesic effect of Trigonella foenum (TFG) leaves extract. J Ethnopharmacol 3-8-2006;104(1-2):108-112. PubMed
  16. Mora, A., Herrrera, A., Lopez, C., Dahbi, G., Mamani, R., Pita, J. M., Alonso, M. P., Llovo, J., Bernardez, M. I., Blanco, J. E., Blanco, M., and Blanco, J. Characteristics of the Shiga-toxin-producing enteroaggregative Escherichia coli O104:H4 German ou
  17. Blanco, J. [Stx2a-producing enteroaggregative Escherichia coli O104:H4-ST678. Microbiological diagnostic already, for this and other STEC/VTEC serotypes!]. Enferm.Infecc.Microbiol.Clin. 2012;30(2):84-89.
  18. Beutin, L. and Martin, A. Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains. J Food Prot. 2012;75(2):408-418. PubMed
  19. King LA, Nogareda F, Weill FX, Mariani-Kurkdjian P, Loukiadis E, Gault G, Jourdan-DaSilva N, Bingen E, Macé M, Thevenot D, Ong N, Castor C, Noël H, Van Cauteren D, Charron M, Vaillant V, Aldabe B, Goulet V, Delmas G, Couturier E, Le Strat Y, Combe C, Delm
  20. Reeder C, Legrand A, O'Connor-Von SK. The Effect of Fenugreek on Milk Production and Prolactin Levels in Mothers of Preterm Infants. Clinical Lactation 2013;4(4):159-165. DOI
  21. Al-Jenoobi FI, Ahad A, Mahrous GM, Al-Mohizea AM, AlKharfy KM, Al-Suwayeh SA. Effects of fenugreek, garden cress, and black seed on theophylline pharmacokinetics in beagle dogs. Pharm Biol 2015;53(2):296-300. PubMed
  22. Rao A, Steels E, Inder WJ, Abraham S, Vitetta L. Testofen, a specialised Trigonella foenum-graecum seed extract reduces age-related symptoms of androgen decrease, increases testosterone levels and improves sexual function in healthy aging males in a doubl
  23. Steels E, Rao A, Vitetta L. Physiological aspects of male libido enhanced by standardized Trigonella foenum-graecum extract and mineral formulation. Phytother Res. 2011 Sep;25(9):1294-300.
  24. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: A meta-analysis. J Ethnopharmacol. 2016 Dec 24;194:260-268. PubMed
  25. Ouzir M, El Bairi K, Amzazi S. Toxicological properties of fenugreek (Trigonella foenum graecum). Food Chem Toxicol. 2016 Oct;96:145-54. PubMed
  26. Khodamoradi K, Khosropanah MH, Ayati Z, et al. The Effects of Fenugreek on Cardiometabolic Risk Factors in Adults: A Systematic Review and Meta-analysis. Complement Ther Med. 2020;52:102416. PubMed
  27. Alkharfy K, Jan B, Alotaibi K, et al. Clopidogrel-herb Interactions: A Pharmacokinetic and Pharmacodynamic Assessment in a Rat Model. Curr Drug Metab 2021;22(12):969-977. PubMed
  28. Bin Jardan YA, Ahad A, Raish M, Alam MA, Al-Mohizea AM, Al-Jenoobi FI. Effects of garden cress, fenugreek and black seed on the pharmacodynamics of metoprolol: an herb-drug interaction study in rats with hypertension. Pharm Biol 2021;59(1):1088-1097. PubMed
  29. Al-Mohizea AM, Ahad A, El-Maghraby GM, et al. Effects of Nigella sativa, Lepidium sativum and Trigonella foenum-graecum on sildenafil disposition in beagle dogs. Eur J Drug Metab Pharmacokinet. 2015;40(2):219-24. PubMed
  30. Alkharfy KM, Al-Jenoobi FI, Al-Mohizea AM, et al. Effects of Lepidium sativum, Nigella sativa and Trigonella foenum-graceum on phenytoin pharmacokinetics in beagle dogs. Phytother Res. 2013;27(12):1800-4.

See these in context on the Fenugreek monograph →

Peppermint 41 references
  1. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-8. PubMed
  2. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5. PubMed
  3. Kline RM, Kline JJ, Di Palma J, Barbero GJ. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001;138:125-8. PubMed
  4. Madisch A, Heydenreich CJ, Wieland V, et al. Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled, double-blind equivalence study. Arzneimittel
  5. May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung 1996;46:1149-53.
  6. Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000;14:20-3. DOI
  7. Morton CA, Garioch J, Todd P, et al. Contact sensitivity to menthol and peppermint in patients with intra-oral symptoms. Contact Dermatitis 1995;32:281-4. PubMed
  8. May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000;14:1671-7. PubMed
  9. Nash P, Gould SR, Bernardo DE. Peppermint oil does not relieve the pain of irritable bowel syndrome. Br J Clin Pract 1986;40:292-3. DOI
  10. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979;2:835-6. PubMed
  11. Davies SJ, Harding LM, Baranowski AP. A novel treatment of postherpetic neuralgia using peppermint oil. Clin J Pain 2002;18:200-2. PubMed
  12. Weston CF. Anal burning and peppermint oil. Postgrad Med J 1987;63:717. PubMed
  13. Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002;72:247-55. PubMed
  14. Wacher VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J Pharm Sci 2002;91:77-90.
  15. Lawson MJ, Knight RE, Tran K, et al. Failure of enteric-coated peppermint oil in the irritable bowel syndrome: a randomized double-blind crossover study. J Gastroenterol Hepatol 1988;3:235-8. DOI
  16. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  17. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001;53:1323-9. PubMed
  18. Rogers SN, Pahor AL. A form of stomatitis induced by excessive peppermint consumption. Dent Update 1995;22:36-7.
  19. Cappello G, Spezzaferro M, Grossi L, et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis 2007;39:530-6. PubMed
  20. Moghadam BK, Gier R, and Thurlow T. Extensive oral mucosal ulcerations caused by misuse of a commercial mouthwash. Cutis 1999;64:131-134.
  21. Andersen, K. E. Contact allergy to toothpaste flavors. Contact Dermatitis 1978;4(4):195-198. PubMed
  22. Barnard, D. R. Repellency of essential oils to mosquitoes (Diptera: Culicidae). J Med Entomol. 1999;36(5):625-629. PubMed
  23. Tamir, S., Davidovich, Z., Attal, P., and Eliashar, R. Peppermint oil chemical burn. Otolaryngol.Head Neck Surg. 2005;133(5):801-802. PubMed
  24. Kalavala, M., Hughes, T. M., Goodwin, R. G., Anstey, A. V., and Stone, N. M. Allergic contact dermatitis to peppermint foot spray. Contact Dermatitis 2007;57(1):57-58. PubMed
  25. Vermaat, H., van Meurs, T., Rustemeyer, T., Bruynzeel, D. P., and Kirtschig, G. Vulval allergic contact dermatitis due to peppermint oil in herbal tea. Contact Dermatitis 2008;58(6):364-365. PubMed
  26. Merat, S., Khalili, S., Mostajabi, P., Ghorbani, A., Ansari, R., and Malekzadeh, R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig.Dis.Sci. 2010;55(5):1385-1390. PubMed
  27. Tran, A., Pratt, M., and DeKoven, J. Acute allergic contact dermatitis of the lips from peppermint oil in a lip balm. Dermatitis 2010;21(2):111-115. DOI
  28. Hitz, Lindenmuller, I and Lambrecht, J. T. Oral care. Curr Probl.Dermatol 2011;40:107-115.
  29. Shavakhi, A., Ardestani, S. K., Taki, M., Goli, M., and Keshteli, A. H. Premedication with peppermint oil capsules in colonoscopy: a double blind placebo-controlled randomized trial study. Acta Gastroenterol Belg 2012;75(3):349-353.
  30. Lech, Y., Olesen, K. M., Hey, H., Rask-Pedersen, E., Vilien, M., and Ostergaard, O. [Treatment of irritable bowel syndrome with peppermint oil. A double- blind study with a placebo]. Ugeskr.Laeger 10-3-1988;150(40):2388-2389.
  31. Parys, B. T. Chemical burns resulting from contact with peppermint oil mar: a case report. Burns Incl.Therm.Inj. 1983;9(5):374-375. PubMed
  32. Bayat R, Borici-Mazi R. A case of anaphylaxis to peppermint. Allergy Asthma Clin Immunol. 2014;10(1):6. PubMed
  33. Rich G, Shah A, Koloski N, et al. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol Motil 2 PubMed
  34. Douros A, Bronder E, Andersohn F, et al. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. Int J Mol Sci 2016;17(1). PubMed
  35. Begas E, Tsioutsiouliti A, Kouvaras E, et al. Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. Food Chem Toxicol 2017;100:80-9 PubMed
  36. Cash BD, Epstein MS, Shah SM. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. Dig Dis Sci 2016;61(2):560-71. PubMed
  37. Elsaie LT, El Mohsen AM, Ibrahim IM, Mohey-Eddin MH, Elsaie ML. Effectiveness of topical peppermint oil on symptomatic treatment of chronic pruritus. Clin Cosmet Investig Dermatol 2016;9:333-8. PubMed
  38. Wu J, Xu R, Zhan R, et al. Effective symptomatic treatment for severe and intractable pruritus associated with severe burn-induced hypertrophic scars: A prospective, multicenter, controlled trial. Burns 2016;42(5):1059-66. PubMed
  39. Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123-136. PubMed
  40. Nee J, Ballou S, Kelley JM, et al. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. Am J Gastroenterol 2021;116(11):2279-2285. PubMed
  41. Ingrosso MR, Ianiro G, Nee J, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 2022;56(6):932-41. PubMed

See these in context on the Peppermint monograph →

Eucalyptus 23 references
  1. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  2. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;1 PubMed
  3. De Vincenzi M, Silano M, De Vincenzi A, et al. Constituents of aromatic plants: eucalyptol. Fitoterapia 2002;73:269-75. PubMed
  4. Gray AM, Flatt PR. Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) are associated with pancreatic and extra-pancreatic effects in mice. J Nutr 1998;128:2319-23. PubMed
  5. Whitman BW, Ghazizadeh H. Eucalyptus oil: therapeutic and toxic aspects of pharmacology in humans and animals. J Paediatr Child Health 1994;30:190-1. PubMed
  6. Barker SC and Altman PM. An ex vivo, assessor blind, randomised, parallel group, comparative efficacy trial of the ovicidal activity of three pediculicides after a single application--melaleuca oil and lavender oil, eucalyptus oil and lemon tea tree oil,
  7. Vilaplana, J. and Romaguera, C. Allergic contact dermatitis due to eucalyptol in an anti-inflammatory cream. Contact Dermatitis 2000;43(2):118.
  8. Juergens, U. R. [Reducing the need for cortisone. Does eucalyptus oil work in asthma? (interview by Brigitte Moreano]. MMW.Fortschr Med 3-29-2001;143(13):14.
  9. Tascini, C., Ferranti, S., Gemignani, G., Messina, F., and Menichetti, F. Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract. Clin Microbiol.Infect. 2002;8(7):437, 445-437, 446. PubMed
  10. Galdi, E., Perfetti, L., Calcagno, G., Marcotulli, M. C., and Moscato, G. Exacerbation of asthma related to Eucalyptus pollens and to herb infusion containing Eucalyptus. Monaldi Arch.Chest Dis. 2003;59(3):220-221.
  11. Spoerke, D. G., Vandenberg, S. A., Smolinske, S. C., Kulig, K., and Rumack, B. H. Eucalyptus oil: 14 cases of exposure. Vet Hum.Toxicol 1989;31(2):166-168.
  12. Jori, A., Bianchetti, A., Prestini, P. E., and Gerattini, S. Effect of eucalyptol (1,8-cineole) on the metabolism of other drugs in rats and in man. Eur.J Pharmacol 1970;9(3):362-366. PubMed
  13. Tibballs, J. Clinical effects and management of eucalyptus oil ingestion in infants and young children. Med J Aust 8-21-1995;163(4):177-180. PubMed
  14. Webb, N. J. and Pitt, W. R. Eucalyptus oil poisoning in childhood: 41 cases in south-east Queensland. J Paediatr.Child Health 1993;29(5):368-371. PubMed
  15. Gyldenløve M, Menné T, Thyssen JP. Eucalyptus contact allergy. Contact Dermatitis. 2014;71(5):303-304. PubMed
  16. Higgins C, Palmer A, Nixon R. Eucalyptus oil: contact allergy and safety. Contact Dermatitis. 2015;72(5):344-346. PubMed
  17. de Groot AC, Schmidt E. Eucalyptus oil and tea tree oil. Contact Dermatitis. 2015;73(6):381-386. PubMed
  18. Greive KA, Barnes TM. The efficacy of Australian essential oils for the treatment of head lice infestation in children: A randomised controlled trial. Australas J Dermatol. 2018;59(2):e99-e105. PubMed
  19. Paulsen E, Thormann H, Vestergaard L. Eucalyptus species as a cause of airborne allergic contact dermatitis. Contact Dermatitis. 2018;78(4):301-303.
  20. Mathew T, John SK, Kamath V, et al. Essential oil related seizures (EORS): A multi-center prospective study on essential oils and seizures in adults. Epilepsy Res. 2021;173:106626. PubMed
  21. Dudipala SC, Mandapuram P, Ch LK. Eucalyptus Oil-Induced Seizures in Children: Case Reports and Review of the Literature. J Neurosci Rural Pract 2021;12(1):112-115. PubMed
  22. Panda PK, Sharawat IK, Panda P, Dawman L, Kasinathan A. Clinico-laboratory characteristics and outcome of patients with eucalyptus oil-induced/provoked seizures: A case series and systematic review of the published patients. Trop Doct 2021;51(4):518-522. PubMed
  23. Sai Chandar D, Prashanthi M, Laxman Kumar C, Amith Kumar C. Eucalyptus Oil-Induced Seizures in Children: A Single-Center Prospective Study. Cureus 2021;13(3):e14109. PubMed

See these in context on the Eucalyptus monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring